EARLY signals of progressive supranuclear palsy are emerging from large-scale data, with depression and gut disorders identified years before diagnosis, offering clinicians a potential window to recognise this rare neurodegenerative condition sooner and intervene more effectively.
Background to Progressive Supranuclear Palsy Risk
Progressive supranuclear palsy remains a poorly understood tauopathy, often misdiagnosed due to overlapping motor and cognitive features. Using UK Biobank data, researchers examined early health patterns linked to progressive supranuclear palsy, aiming to clarify epidemiological risk factors across a large, population-based cohort followed over two decades.
Methods and Key Findings
Researchers conducted a matched nested case control analysis of over 500000 adults aged 37 to 73 years, identifying 240 incident cases of progressive supranuclear palsy. Depression showed an odds ratio of 3.22 with 95% confidence interval 2.30 to 4.50 and P < 0.001, while delirium had an odds ratio of 6.76 with 95% confidence interval 4.08 to 11.19 and P < 0.001. Functional gastrointestinal disorders were also associated with risk with odds ratio 1.91 with 95% confidence interval 1.39 to 2.63 and P < 0.001. Heavy alcohol use increased risk odds ratio 1.65 with 95% confidence interval 1.21 to 2.26 and P = 0.0017.
Clinical Implications and Future Directions
These findings indicate that progressive supranuclear palsy may have a prolonged premotor phase characterised by neuropsychiatric and gastrointestinal symptoms that precede diagnosis by five to ten years. Clinicians should consider earlier neurological evaluation in patients presenting with persistent depression, delirium episodes, or functional bowel disorders, particularly when combined with atypical motor complaints. The inverse association with cancer, odds ratio 0.56 with 95% confidence interval 0.40 to 0.79 and P < 0.001, suggests shared biological mechanisms that warrant further investigation. Future research should focus on mechanistic pathways, risk stratification tools, and targeted surveillance strategies to improve early detection and refine clinical trial recruitment in progressive supranuclear palsy. Integration of longitudinal biomarkers, imaging signatures, and digital health monitoring could enhance predictive accuracy and support personalised management pathways for individuals identified as high risk within population-level screening frameworks in routine clinical practice settings globally.
Reference
Zhao CW et al. Risk factors for the diagnosis of progressive supranuclear palsy in the UK Biobank. Mov Disord. 2026;DOI:10.1002/mds.70287.
